Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mesoblast Limited ( (AU:MSB) ) has issued an announcement.
Mesoblast Limited has announced the issuance of 5,000,000 warrants to investors as part of a convertible note subscription agreement, allowing for the potential raising of up to US$50 million. This move, following shareholder approval, aims to provide the company with financial flexibility to repay or reduce existing loans and support general working capital needs, potentially impacting its financial stability and market positioning.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company focused on developing and commercializing innovative cellular medicines. The company operates in the regenerative medicine industry, with a primary focus on developing treatments for inflammatory diseases, cardiovascular conditions, and back pain.
Average Trading Volume: 4,876,993
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.55B
Learn more about MSB stock on TipRanks’ Stock Analysis page.